Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms
Abstract Prolactin (PRL) is elevated in B-cell mediated lymphoproliferative diseases and promotes B-cell survival. However, whether PRL or PRL receptors drive the initiation, establishment, and sustenance of B-cell malignancies is unknown. We measured changes in B cells after knocking down the pro-proliferative, anti-apoptotic long isoform of the PRL receptor (LFPRLR) in vivo in systemic lupus erythematosus (SLE)- and B-cell lymphoma-prone mouse models, and the LFPRLR plus intermediate isoforms (LF/IFPRLR) in vitro in malignant human B cells. To knockdown LF/IFPRLRs without suppressing expression of the counteractive short PRLR isoforms (SFPRLRs), we employed splice-modulating DNA oligomers. In SLE-prone mice, LFPRLR knockdown reduced numbers and proliferation of B-cell subsets and lowered the risk of B-cell transformation by downregulating expression of activation-induced cytidine deaminase. LFPRLR knockdown in lymphoma-prone mice reduced B-cell numbers and their expression of BCL2. In overt human B-cell malignancies, LF/IFPRLR knockdown reduced B-cell viability and their MYC and BCL2 expression. Unlike their normal counterparts which produced no autocrine PRL and expressed SFPRLRs, malignant human B cells expressed autocrine PRL and often no SFPRLRs. Isoform-specific knockdown of the LF/IFPRLR was not toxic to mice or to normal human immune cells, suggesting it is a safe approach to block the evolution of B-cell malignancies..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 21. März Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khani, Adeleh Taghi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2022831/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA037383132 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA037383132 | ||
| 003 | DE-627 | ||
| 005 | 20231205145939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220925s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2022831/v1 |2 doi | |
| 035 | |a (DE-627)XRA037383132 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2022831/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khani, Adeleh Taghi |e verfasserin |0 (orcid)0000-0003-4978-593X |4 aut | |
| 245 | 1 | 0 | |a Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Prolactin (PRL) is elevated in B-cell mediated lymphoproliferative diseases and promotes B-cell survival. However, whether PRL or PRL receptors drive the initiation, establishment, and sustenance of B-cell malignancies is unknown. We measured changes in B cells after knocking down the pro-proliferative, anti-apoptotic long isoform of the PRL receptor (LFPRLR) in vivo in systemic lupus erythematosus (SLE)- and B-cell lymphoma-prone mouse models, and the LFPRLR plus intermediate isoforms (LF/IFPRLR) in vitro in malignant human B cells. To knockdown LF/IFPRLRs without suppressing expression of the counteractive short PRLR isoforms (SFPRLRs), we employed splice-modulating DNA oligomers. In SLE-prone mice, LFPRLR knockdown reduced numbers and proliferation of B-cell subsets and lowered the risk of B-cell transformation by downregulating expression of activation-induced cytidine deaminase. LFPRLR knockdown in lymphoma-prone mice reduced B-cell numbers and their expression of BCL2. In overt human B-cell malignancies, LF/IFPRLR knockdown reduced B-cell viability and their MYC and BCL2 expression. Unlike their normal counterparts which produced no autocrine PRL and expressed SFPRLRs, malignant human B cells expressed autocrine PRL and often no SFPRLRs. Isoform-specific knockdown of the LF/IFPRLR was not toxic to mice or to normal human immune cells, suggesting it is a safe approach to block the evolution of B-cell malignancies. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Kumar, Anil |4 aut | |
| 700 | 1 | |a Ortiz, Ashly Sanchez |4 aut | |
| 700 | 1 | |a Radecki, Kelly |4 aut | |
| 700 | 1 | |a Lee, Sung June |4 aut | |
| 700 | 1 | |a Hu, Zunsong |0 (orcid)0000-0003-3167-7148 |4 aut | |
| 700 | 1 | |a Damirchi, Behzad |4 aut | |
| 700 | 1 | |a Lorenson, Mary |4 aut | |
| 700 | 1 | |a Wu, Xiwei |4 aut | |
| 700 | 1 | |a Gu, Zhaohui |0 (orcid)0000-0003-1581-1327 |4 aut | |
| 700 | 1 | |a Stohl, William |0 (orcid)0000-0002-8272-7873 |4 aut | |
| 700 | 1 | |a Sanz, Ignacio |0 (orcid)0000-0003-4182-587X |4 aut | |
| 700 | 1 | |a Meffre, Eric |4 aut | |
| 700 | 1 | |a Müschen, Markus |0 (orcid)0000-0002-6064-8613 |4 aut | |
| 700 | 1 | |a Forman, Stephen |0 (orcid)0000-0002-2803-4152 |4 aut | |
| 700 | 1 | |a Koff, Jean |0 (orcid)0000-0003-4414-0489 |4 aut | |
| 700 | 1 | |a Walker, Ameae |4 aut | |
| 700 | 1 | |a Swaminathan, Srividya |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 21. März |
| 773 | 1 | 8 | |g year:2023 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s42003-023-04667-8 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2022831/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 21 |c 03 | ||